azn201304296k1.htm
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2013

 
Commission File Number: 001-11960

 
AstraZeneca PLC
 
 
2 Kingdom Street, London W2 6BD
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X      Form 40-F __
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______           
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
Yes __     No X
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 


 

 
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
 
On 26 April 2013, Dame Nancy Rothwell, a Director of the Company notified us that, on 26 April 2013, she purchased 238 AstraZeneca PLC Ordinary Shares of $0.25 each at a price of 3320 pence per share.
 
Following this purchase, Dame Nancy Rothwell has a total interest in 2,643 AstraZeneca shares.
 
 
A C N Kemp
Company Secretary
29 April 2013
  
 
  
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 29 April 2013
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary